Almost every GLP-1 medication label, including semaglutide, tirzepatide, liraglutide, dulaglutide, and once-weekly exenatide, carries a boxed warning about thyroid tumors. It's often one of the first things people notice and worry about before starting. The warning is real, but what it means for you depends almost entirely on your personal and family history.
What the warning says
Most GLP-1 receptor agonists carry an FDA boxed warning, the most serious category of drug warning. It says not to use the drug if you have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). Two older, short-acting drugs are exceptions and carry no thyroid boxed warning: twice-daily exenatide (Byetta (external link)) and lixisenatide, sold in the US in the insulin combination Soliqua (external link). A note on availability, as of September 2026: in August 2024 AstraZeneca told the FDA it would permanently stop marketing both Byetta and Bydureon BCise (once-weekly exenatide) in the US, although exenatide has also been approved as a generic (FDA pharmacovigilance review, April 2025 (external link)).
The warning comes from rodent studies, where GLP-1 receptor activation was linked to C-cell tumors in the thyroid (Kelly & Sipos, Journal of Clinical Endocrinology & Metabolism, 2025, DOI (external link)). That mechanism doesn't clearly carry over to people. Laboratory work found that human and monkey thyroid C-cells have low GLP-1 receptor expression, the drugs didn't trigger calcitonin release in primates, and 20 months of liraglutide at more than 60 times human exposure didn't cause C-cell hyperplasia in monkeys. The same researchers note that the long-term effects of GLP-1 receptor activation in the human thyroid are still unknown (Bjerre Knudsen et al., Endocrinology, 2010, DOI (external link)).
What's clear and what's still debated
The clear part covers one group. If you have a personal or family history of MTC or MEN 2, you should not use the GLP-1 medications that carry this warning, which is nearly all of them.
Less clear is whether these drugs raise the risk of differentiated thyroid cancer in everyone else. That's a different, more common, and generally more treatable type of thyroid cancer than MTC. The 2025 Kelly and Sipos review found some studies suggest a higher incidence in GLP-1 users while others don't, and there's no consensus. The most-cited signal is a large French national case-control study in people with type 2 diabetes, which found a higher risk of thyroid cancer after 1–3 years of GLP-1 use (adjusted HR 1.58; MTC HR 1.78). It was observational and can't rule out detection bias (Bezin et al., Diabetes Care, 2023, DOI (external link)). A Scandinavian cohort of more than 145,000 GLP-1 users, followed for an average of 3.9 years, found no increased risk (HR 0.93) (Pasternak et al., BMJ, 2024, DOI (external link)).
For broader context, a 2025 meta-analysis of trials covering nearly 100,000 patients found no significant difference in overall tumor rates between GLP-1 treatment and placebo, though it didn't look at thyroid cancer specifically (Galli et al., JACC, 2025, DOI (external link)).
What this means for screening
There's no clear consensus on routine screening, such as thyroid ultrasounds or calcitonin blood tests, before or during GLP-1 treatment for people without a personal or family history of MTC or MEN 2. Guidance is still developing. Ask your prescriber about it, especially if you have a personal risk factor such as a thyroid nodule found by chance on other imaging.
What to tell your prescriber
Make sure your prescriber knows your full personal and family thyroid history before you start. It's the one piece of information that directly decides whether these medications are appropriate for you at all. Beyond that group, the evidence on broader thyroid cancer risk is mixed and unsettled: worth knowing, but not a reason for alarm if you don't have those risk factors.
Study findings above are attributed to their authors and were located via PubMed.
This is general education, not medical advice. Share your full personal and family thyroid history with your prescriber before starting a GLP-1 medication, and take any questions about your own risk to them.